Baxter International Inc.
BTL.DE
Deutsche Börse58.80
EUR
- -
- -
Baxter International Inc.
BTL.DE
(Deutsche Börse)
Recent
price
58.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Baxter International Inc. (NYSE:BAX; FSE:BTL) develops, manufactures and markets a broad portfolio of essential medical products and therapies that save and sustain lives worldwide; core offerings span Medical Products and Therapies including intravenous solutions, infusion pumps such as Spectrum IQ and Novum IQ, administration sets, parenteral nutrition, surgical hemostats, sealants and adhesion prevention products; Healthcare Systems and Technologies encompassing front-line care solutions like smart bed systems, patient monitoring devices including Welch Allyn Connex360 Vital Monitor, diagnostic technologies, respiratory health devices, operating room integration technologies and precision positioning devices; and Pharmaceuticals featuring specialty injectable pharmaceuticals, inhaled anesthetics, drug compounding services, pain management, critical care, anti-infection and oncology products. Founded in 1931 and headquartered in Deerfield, Illinois, the company serves hospitals, clinics, dialysis centers, nursing homes, physicians' offices and home care patients across the Americas, Europe, Middle East and Africa, Asia-Pacific and Latin America through approximately 38,000 employees; it reports global net sales of $14.8 billion in 2023, with third-quarter 2025 continuing operations sales reaching $2.84 billion, up 5% reported. Recent developments include the January 2025 sale of its Kidney Care business (Vantive) to Carlyle Group for $3.8 billion, enabling debt reduction from the 2021 $12.5 billion Hillrom acquisition and a new operating model focused on cost optimization; ongoing integration of Hillrom with related expenses and property impairments; launch of the Welch Allyn Connex360 Vital Monitor and Novum IQ Large Volume Pump; first-ever Gold Level resiliency recognition from Resilinc for IV, nutrition and premix drugs; business optimization initiatives post-Kidney Care divestiture including workforce reductions and facility exits; remediation from Hurricane Helene impacts at its North Carolina IV fluid plant causing temporary U.S. shortages; and updated 2025 guidance projecting 4-5% reported sales growth from continuing operations with adjusted diluted EPS of $2.35-$2.40.